Authors
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
The American Board of Urology: Considerations for the urologist in career transitions"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.
Latest:
UCI receives renewal as Orange County’s only federally designated comprehensive cancer centerThe National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation
Latest:
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.
Latest:
Looking Ahead: Image-Guided Diagnostic ToolsKyrollis Attalla, MD, remarks on emerging imaging technologies for patients with prostate cancer and the growing pool of candidates for focal therapy.
Latest:
Legislative efforts to eliminate barriers to prostate cancer screening ramp up"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.
Latest:
Final Thoughts and Clinical Trials in NMIBCExperts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Latest:
2024 Urology Times pipeline reportCatch up on all the notable drug and device approvals in urology over the past year.
Latest:
MIPS success: What specialists need to know"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.
Latest:
Recognizing hereditary syndromes in renal cell carcinomaPatients may require specific diagnostic, surveillance, and therapeutic management.
Latest:
Patient selection for cytoreductive nephrectomy in 2025"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Latest:
Low-intensity shockwave therapy, plasma injections efficacious for erectile dysfunctionSMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.
Latest:
EBRT not linked to increased hematological toxicity for mCRPC treated with Ra-233Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.
Latest:
National Women’s Health Week: Celebrating women shaping the future of urology"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancerThe miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Explaining Study Results to Your PatientsA panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when added to hormone therapy while emphasizing that darolutamide may cause fewer central nervous system adverse effects like fatigue and cognitive changes, helping patients understand the potential benefits and tradeoffs to make a treatment decision that best fits their individual situation and preferences.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Considerations for choosing an AI scribe toolAI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.
Latest:
Key Takeaways on the Evolving NMIBC Treatment LandscapeThe panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet NeedsIn this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.
Latest:
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
Latest:
Patient selection for cytoreductive nephrectomy in 2025"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Latest:
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.
